What is the difference between Mvasi and Avastin?
Mvasi (bevacizumab-awwb) is a biosimilar to Avastin (bevacizumab).
Mvasi is not interchangeable with Avastin. The prescriber must write a prescription specifically for Mvasi.
A biosimilar, according to the FDA, is a biological product that is highly similar to an FDA-approved biological product, known as a reference product (in this case Avastin), and has no clinically meaningful differences in terms of safety and effectiveness.
See Biosimilar and Interchangeable Biologics: More Treatment Choices
Mvasi has the same approved indications as Avastin, with the exception of hepatocellular carcinoma.
Avastin | Mvasi | |
---|---|---|
Generic Name | bevacizumab | bevacizumab-awwb |
How Supplied |
|
|
Indications |
|
|
Mvasi was approved in 2017 as the first biosimilar to Avastin. A second Avastin biosimilar called Zirabev (bevacizumab-bvzr) was approved in 2019, and a third called Alymsys (bevacizumab-maly) was approved in 2022.
Related questions
Read next
What are anti-VEGF drugs (VEGF inhibitors)?
Anti-VEGF drugs slow the abnormal growth of blood vessels associated with certain cancers and degenerative eye conditions, such as age-related macular degeneration. Anti-VEGF stands for anti-vascular endothelial growth factor. Continue reading
Is small cell or non-small cell lung cancer worse?
Generally, small cell lung cancer (SCLC) is worse than non-small cell lung cancer (NSCLC). SCLC accounts for about 10-15% of people who have lung cancer and is the most aggressive form of lung cancer. SCLC usually starts in the breathing tubes (bronchi), and although the cells are small, they grow very quickly and create large tumors. Early on in the course of the disease, there are rarely any symptoms. If caught early (limited-stage disease) 20-25% of people can be potentially cured. Extensive SCLC is more difficult to treat. Continue reading
Is non-small cell lung cancer hereditary?
A hereditary family history of lung cancer is one of the many risk factors for developing non-small cell lung cancer. About 8% of lung cancers are thought to be inherited or linked to gene changes, but smoking and air pollution remain the primary causes of lung cancer. Continue reading
Related medical questions
- What are biologic drugs and how do they work?
- What biosimilars have been approved in the United States?
- How aggressive is non-small cell lung cancer?
- Does smoking cause non-small cell lung cancer?
- What type of lung cancer is Vizimpro used to treat?
- What type of cancer is Tecentriq used to treat?
- How long does it take for Keytruda to work?
- Why give Taxol (Paxel) before carboplatin?
- What is the difference between Opdivo and Keytruda?
- Pembrolizumab vs. nivolumab: How do they compare?
- What is Paxel called in the USA?
- How effective is Lumakras, what's the survival rate?
- Are there cost-saving programs for Tecentriq?
- How effective is Tabrecta?
- How does erlotinib work (mechanism of action)?
- How effective is atezolizumab (Tecentriq)?
- Is atezolizumab (Tecentriq) a chemotherapy or immunotherapy drug?
- Opdivo vs Opdivo Qvantig: What is the Difference?
- How long can I take Gilotrif (afatinib) for?
- Will Tabrecta cure lung cancer?
- How long do you take Alecensa for?
- Is Gilotrif (afatinib) a chemotherapy drug?
- How effective is Alecensa for ALK-positive NSCLC?
- How does Retevmo work?
- Is Tabrecta a chemotherapy drug?
- What is the mechanism of action for Alecensa (alectinib)?
- Can Tarceva (erlotinib) cure lung cancer?
- How does pemetrexed work?
- How do Exkivity and Rybrevant compare for NSCLC?
- How does Rybrevant work?
Drug information
Related support groups
- Avastin (9 questions, 46 members)
- Bevacizumab (4 questions, 7 members)
- Mvasi (3 questions, 5 members)
- Non-Small Cell Lung Cancer (53 questions, 72 members)
- Renal Cell Carcinoma (32 questions, 103 members)
- Colorectal Cancer (19 questions, 53 members)
- Cervical Cancer (6 questions, 25 members)
- Glioblastoma Multiforme (1 questions, 27 members)